tradingkey.logo

Grail Inc

GRAL

35.920USD

-0.690-1.88%
Fechamento 07/17, 16:00ETCotações atrasadas em 15 min
1.27BValor de mercado
PerdaP/L TTM

Grail Inc

35.920

-0.690-1.88%
Mais detalhes de Grail Inc Empresa
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
Informações da empresa
Código da empresaGRAL
Nome da EmpresaGrail Inc
Data de listagemJun 12, 2024
Fundado em2020
CEOMr. Robert (Bob) Ragusa
Número de funcionários1000
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 12
Endereço1525 O'brien Drive
CidadeMENLO PARK
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94025
Telefone18336942553
Sitehttps://grail.com/
Código da empresaGRAL
Data de listagemJun 12, 2024
Fundado em2020
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Aaron Freidin
Mr. Aaron Freidin
Chief Financial Officer
Chief Financial Officer
83.87K
-32.92%
Ms. Sarah Krevans
Ms. Sarah Krevans
Independent Director
Independent Director
68.19K
+9.79%
Mr. Gregory L. (Greg) Summe
Mr. Gregory L. (Greg) Summe
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
11.07K
+121.83%
Mr. William J. (Bill) Chase
Mr. William J. (Bill) Chase
Independent Director
Independent Director
9.31K
+188.30%
Mr. Alex Dobbin
Mr. Alex Dobbin
IR Contact Officer
IR Contact Officer
--
--
Mr. Andy Partridge
Mr. Andy Partridge
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Robert (Bob) Ragusa
Mr. Robert (Bob) Ragusa
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Joshua (Josh) Ofman, M.D.
Mr. Joshua (Josh) Ofman, M.D.
President
President
--
--
Mr. Steve Mizell
Mr. Steve Mizell
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Aaron Freidin
Mr. Aaron Freidin
Chief Financial Officer
Chief Financial Officer
83.87K
-32.92%
Ms. Sarah Krevans
Ms. Sarah Krevans
Independent Director
Independent Director
68.19K
+9.79%
Mr. Gregory L. (Greg) Summe
Mr. Gregory L. (Greg) Summe
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
11.07K
+121.83%
Mr. William J. (Bill) Chase
Mr. William J. (Bill) Chase
Independent Director
Independent Director
9.31K
+188.30%
Mr. Alex Dobbin
Mr. Alex Dobbin
IR Contact Officer
IR Contact Officer
--
--
Mr. Andy Partridge
Mr. Andy Partridge
Chief Commercial Officer
Chief Commercial Officer
--
--
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2025Q1
Por EmpresaUSD
Nome
Receita
Proporção
Screening
29.13M
91.51%
Development Services
2.70M
8.49%
Por RegiãoUSD
Nome
Receita
Proporção
United States
28.96M
90.96%
International
2.88M
9.04%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Screening
29.13M
91.51%
Development Services
2.70M
8.49%
Distribuição de ações
Atualizado em: sáb, 17 de mai
Atualizado em: sáb, 17 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Illumina Inc
12.52%
CRCM L.P.
10.13%
PRIMECAP Management Company
5.70%
Baker Bros. Advisors LP
4.53%
Sessa Capital
4.19%
Other
62.93%
Investidores
Investidores
Proporção
Illumina Inc
12.52%
CRCM L.P.
10.13%
PRIMECAP Management Company
5.70%
Baker Bros. Advisors LP
4.53%
Sessa Capital
4.19%
Other
62.93%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
32.07%
Investment Advisor
17.70%
Hedge Fund
14.59%
Corporation
12.52%
Research Firm
1.73%
Individual Investor
1.36%
Pension Fund
0.37%
Bank and Trust
0.35%
Sovereign Wealth Fund
0.19%
Other
19.12%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
859
29.02M
80.66%
-2.71M
2025Q1
859
29.51M
82.19%
-2.62M
2024Q4
810
31.24M
92.16%
+4.27M
2024Q3
748
27.13M
81.56%
+4.49M
2024Q2
646
27.14M
86.18%
+27.14M
2024Q1
2
135.00
0.00%
+135.00
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Illumina Inc
4.50M
12.52%
+4.50M
--
Jun 30, 2024
CRCM L.P.
3.64M
10.13%
--
--
Mar 31, 2025
PRIMECAP Management Company
2.05M
5.7%
-27.84K
-1.34%
Mar 31, 2025
Baker Bros. Advisors LP
1.63M
4.53%
--
--
Mar 31, 2025
Sessa Capital
1.51M
4.19%
-410.20K
-21.38%
Apr 30, 2025
The Vanguard Group, Inc.
1.49M
4.15%
+47.45K
+3.28%
Mar 31, 2025
AQR Capital Management, LLC
1.34M
3.72%
+506.44K
+60.96%
Mar 31, 2025
State Street Global Advisors (US)
1.27M
3.52%
+131.25K
+11.55%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.12M
3.1%
-136.18K
-10.88%
Mar 31, 2025
Arbiter Partners Capital Management, LLC
1.03M
2.85%
+194.40K
+23.40%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: dom, 6 de jul
Atualizado em: dom, 6 de jul
Nome
Proporção
ROBO Global Healthcare Technology & Innovation ETF
1.54%
BNY Mellon Innovators ETF
0.93%
Franklin Genomic Advancements ETF
0.89%
SPDR S&P Biotech ETF
0.55%
Direxion Daily S&P Biotech Bull 3X Shares
0.34%
ProShares Ultra Nasdaq Biotechnology
0.21%
Invesco Nasdaq Biotechnology ETF
0.14%
Optimize Strategy Index ETF
0.12%
Invesco Russell 1000 Equal Weight ETF
0.12%
iShares Biotechnology ETF
0.11%
Ver Mais
ROBO Global Healthcare Technology & Innovation ETF
Proporção1.54%
BNY Mellon Innovators ETF
Proporção0.93%
Franklin Genomic Advancements ETF
Proporção0.89%
SPDR S&P Biotech ETF
Proporção0.55%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.34%
ProShares Ultra Nasdaq Biotechnology
Proporção0.21%
Invesco Nasdaq Biotechnology ETF
Proporção0.14%
Optimize Strategy Index ETF
Proporção0.12%
Invesco Russell 1000 Equal Weight ETF
Proporção0.12%
iShares Biotechnology ETF
Proporção0.11%
Dividendo
Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
KeyAI